EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Epstein-Barr Virus InfectionsPrimary Immune Deficiency Disorder
Interventions
DRUG

cytotoxic t-lymphocytes

EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.

Trial Locations (8)

10595

RECRUITING

New York Medical College, Valhalla

19104

RECRUITING

Children's Hospital of Pennsylvania, Philadelphia

21287

RECRUITING

Johns Hopkins, Baltimore

43205

RECRUITING

Nationwide Children's Hosptial, Columbus

53226

RECRUITING

Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee

63130

RECRUITING

Washington University, St Louis

90027

RECRUITING

Children's Hosptial Los Angeles, Los Angeles

94158

RECRUITING

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

Nationwide Children's Hospital

OTHER

collaborator

Indiana University

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

University of California, Los Angeles

OTHER

collaborator

University of California, San Francisco

OTHER

lead

New York Medical College

OTHER